Arsanis, Inc. Appoints Michael P. Gray As Chief Financial Officer And Chief Business Officer

WALTHAM, Mass. & VIENNA, Austria--(BUSINESS WIRE)--Arsanis, Inc., a clinical-stage biopharmaceutical company focused on monoclonal antibody approaches for the prevention and treatment of serious infectious diseases, today announced that Michael P. Gray has joined the company as chief financial officer and chief business officer.

Suggested Articles

Antivirals from Roche, Bristol Myers Squibb, Viiv and Gilead, or modified versions of them, could prove effective against COVID-19, researchers said.

After posting positive data that showed it could help slow down the degenerative ALS disease, Amylyx has been given a $30 million boost.

Sumitomo is looking to the merged pipeline to help offset the anticipated impact of the arrival of generic competitors to bipolar drug Latuda.